Protocol Ledger

NCT05213624 · Phase II · COMPLETED

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

Interventional Phase II clinical trial protocol NCT05213624 sponsored by Boehringer Ingelheim in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-03 Enrollment: 67 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05213624
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)67 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05213624
Protocol FieldVerified Registry Value
NCT IdentifierNCT05213624
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment67 participants (ACTUAL)
Registered Start Date2022-05-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI